[go: up one dir, main page]

PE20030835A1 - COMBINACION FARMACEUTICA QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO - Google Patents

COMBINACION FARMACEUTICA QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO

Info

Publication number
PE20030835A1
PE20030835A1 PE2002001166A PE2002001166A PE20030835A1 PE 20030835 A1 PE20030835 A1 PE 20030835A1 PE 2002001166 A PE2002001166 A PE 2002001166A PE 2002001166 A PE2002001166 A PE 2002001166A PE 20030835 A1 PE20030835 A1 PE 20030835A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
receptor agonist
cycloalkyl
adenosine
Prior art date
Application number
PE2002001166A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030835A1 publication Critical patent/PE20030835A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMBINACION INHALADA DE a) UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a DE FORMULA I DONDE R1 ES H, ALQUILO C1-C6 CON FENILO, NAFTILO; R2 ES H, ALQUILO C1-C6; A ES ALQUILENO C1-C6; R3 ES H, ALQUILO C1-C6, -COOR4, CN, -CONR4R4, CICLOALQUILO C3-C8, FENILO, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C8, FENILO; R5 ES ALQUILO C1-C6, CICLOALQUILO C1-C6, FENILO; R6 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C8, FENILO, ENTRE OTROS; R7 ES ALQUILO C1-C6, CICLOALQUILO C3-C8, FENILO, NAFTILO, HET; m ES 0-2. EL COMPUESTO DE FORMULA I ES 9-[(2R,3R, 4S, 5R)-3,4-DIHIDROXI-5-(HIDROXIMETIL)-TETRAHIDRO-2-FURANIL]-6-[(2,2-IFENILETIL)AMINO]-N-[2-(1-PIPERIINIL)ETIL]-9H-PURINA-2-CARBOXAMIDA O UNA DE SUS SALES O SOLVATOS FARMACEUTICAMENTE ACEPTABLES Y b) UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO COMO SALMETEROL. LA COMBINACION ES UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD OBSTRUCTIVA DE LAS VIAS RESPIRATORIAS
PE2002001166A 2001-12-07 2002-12-03 COMBINACION FARMACEUTICA QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO PE20030835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129397.6A GB0129397D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
PE20030835A1 true PE20030835A1 (es) 2003-10-08

Family

ID=9927249

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001166A PE20030835A1 (es) 2001-12-07 2002-12-03 COMBINACION FARMACEUTICA QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO

Country Status (12)

Country Link
US (1) US20030109485A1 (es)
AR (1) AR037709A1 (es)
AU (1) AU2002347532A1 (es)
GB (1) GB0129397D0 (es)
GT (1) GT200200261A (es)
HN (1) HN2002000355A (es)
PA (1) PA8560401A1 (es)
PE (1) PE20030835A1 (es)
SV (1) SV2004001429A (es)
TW (1) TW200303754A (es)
UY (1) UY27565A1 (es)
WO (1) WO2003047628A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547636A1 (en) * 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
SV2004001429A (es) 2004-05-07
GT200200261A (es) 2003-07-11
TW200303754A (en) 2003-09-16
PA8560401A1 (es) 2003-12-10
US20030109485A1 (en) 2003-06-12
WO2003047628A1 (en) 2003-06-12
HN2002000355A (es) 2003-02-21
UY27565A1 (es) 2003-07-31
GB0129397D0 (en) 2002-01-30
AR037709A1 (es) 2004-12-01
AU2002347532A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
PE20010430A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
US20140066396A1 (en) Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
UY27875A1 (es) Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae
AR039891A1 (es) Compuestos tiofen-amidinas, sus composiciones farmaceuticas y su uso para la preparacion de medicamentos para tratar enfermedades y trastornos mediados por c1s
PE20081151A1 (es) Derivados de imidazol como activadores del receptor de adenosina a2a
AR040500A1 (es) Inhibidores de cinasas
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
HUP0400314A2 (hu) Gyógyszer-kombinációk rák kezelésére
CO5150164A1 (es) Derivados de pirazolopiridina
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
PT1412354E (pt) Derivados de triazolil-imidazopiridina e de triazolilpurinas uteis como ligandos do receptor a2a da adenosina e sua utilizacao como medicamentos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
CY1112689T1 (el) Συνθεση για τη βελτιωση της γνωσης και της μνημης
DE60210538D1 (de) Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität
PE20030835A1 (es) COMBINACION FARMACEUTICA QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO
BR0008321A (pt) Secretagogos de hormÈnio de crescimento
PE20030834A1 (es) COMBINACION FARMACEUTICA QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR ß2-ADRENERGICO
BRPI0204489B8 (pt) "derivado de rodamina, composição farmacêutica, intermediário, e, processo para a síntese de novos derivados rodamina".
AR021542A1 (es) Un compuesto de sulfonamida y las composiciones y preparaciones farmaceuticas que lo contienen
AR047730A1 (es) Uso de los derivados de 3-aminocaprolactam como agentes anti-inflamatorios
CO5570673A2 (es) Compuestos azapoliciclicos condensados con arilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal